COLORADO SPRINGS, Colo.--(BUSINESS WIRE)-- Cannabis Science, Inc. (OTCBB: CBIS), a pioneering U.S. biotech company developing pharmaceutical cannabis products, is pleased to announce meetings with Thai Cannabis Corp. and senior government officials and advisors regarding environmental and commercial benefits of medical cannabis.
Cannabis Science and our associates in Thailand are constructing a business relationship that will allow for the necessary clinical trials to take place in Thailand with approval of the Thai governmental. The intent is to formalize a mutually beneficial partnership in the medical cannabis tourism industry. Concurrently, Thailand will serve as a staging ground for Cannabis Science to test and develop our products as we move toward our ultimate goal of U.S. FDA approved cannabis extract based medicines. The Thai people will benefit from our collaborative efforts in that income and knowledge generated by medical cannabis tourism will offset medical costs for the Thai people. It should be noted that Thailand ˗˗ with a population of approximately 68 million ˗˗ has a first class medical system that draws patients from around the world, so everyone can benefit from its integration of medical cannabis into modern health care.
Robert Melamede, Ph.D., Cannabis Science’s CEO stated, “It was amazing to meet with enlightened government officials who recognize the health, environmental, and commercial benefits of hemp and medical cannabis. Thailand now leads the world in having created intelligent policies so that the Thai people, and others from around the world, will benefit from the health promoting properties of the cannabis plant that have been so foolishly suppressed by American led policies of fear and ignorance.”
About Cannabis Science, Inc.
Cannabis Science, Inc. is at the forefront of pharmaceutical grade medical marijuana research and development. The Company works with world authorities on phytocannabinoid science targeting critical illnesses, and adheres to scientific methodologies to develop, produce and commercialize phytocannabinoid-based pharmaceutical products. In sum, we are dedicated to the creation of cannabis-based medicines, both with and without psychoactive properties, to treat disease and the symptoms of disease, as well as for general health maintenance.
Forward Looking Statements
Forward Looking Statements; This Press Release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Act of 1934. A statement containing works such as "anticipate," "seek," intend," "believe," "plan," "estimate," "expect," "project," "plan," or similar phrases may be deemed "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Some or all of the events or results anticipated by these forward-looking statements may not occur. Factors that could cause or contribute to such differences include the future U.S. and global economies, the impact of competition, and the Company's reliance on existing regulations regarding the use and development of cannabis-based drugs. Cannabis Science, Inc. does not undertake any duty nor does it intend to update the results of these forward-looking statements.
CONTACT:
Cannabis Science Inc.
Dr. Robert J. Melamede,President & CEO
1-888-889-0888
[email protected]
or
Investor Relations
Mark J. Friedman
1-877-431-CBIS (2247)
[email protected]
www.cannabisscience.com
KEYWORDS: United States Asia Pacific North America California Colorado Thailand
INDUSTRY KEYWORDS: Health Clinical Trials Public Policy/Government Healthcare Reform Public Policy State/Local Professional Services Other Professional Services
MEDIA: